ArticleFrontiers in microbiology2021
High Prevalence of Extended-Spectrum Beta-Lactamases in
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 46 citations in OpenAlex.
- Phylogenetic Groups, Virulence Factors, and Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2026Article
- Antimicrobial Resistance and ESBL-Associated Predictors Among Uropathogens: A 2019-2024 Isolate-Level Study.Antibiotics (Basel, Switzerland) · 2026Article
- Safety of Short-Term Trimethoprim-Sulfamethoxazole Use for Uncomplicated Cystitis: A Nationwide Retrospective Cohort Study.Pharmacoepidemiology and drug safety · 2026Article
- Carriage of hypervirulent and ESBL-producingApplied and environmental microbiology · 2026Article
- Retrospective study on antibiotic resistance profiles of uropathogenicFrontiers in microbiology · 2026Article
- Molecular characterization of extended spectrum beta-lactamase-producing Enterobacterales from urinary tract infections in Burundi.BMC infectious diseases · 2025Article
- High Prevalence and Genomic Characterization of Extended-SpectrumChina CDC weekly · 2025Article
- High Rates of Antimicrobial Resistance and Emergence of High-Risk Clones in Community-Acquired Uropathogenic Escherichia coli.MicrobiologyOpen · 2025Article
- Analysis of phylogroups, biofilm formation, virulence factors, antibiotic resistance and molecular typing of uropathogenic Escherichia coli strains isolated from patients with recurrent and non-recurrent urinary tract infections.BMC infectious diseases · 2025Article
- Characteristics and spatiotemporal changes in phenotypes and genotypes of extended-spectrum β-lactamases in Escherichia coli isolated from bloodstream infections in China from 2014 to 2021.Annals of clinical microbiology and antimicrobials · 2025Article
- Retrospective Analysis of Antibiotic Resistance Patterns of UropathogenicHealth science reports · 2025Article
- Antimicrobial resistance profile and associated factors of hospital-acquired gram-negative bacterial pathogens among hospitalized patients in northeast Ethiopia.BMC microbiology · 2024Article
- Whole-genome sequencing of multidrug-resistant Escherichia coli causing urinary tract infection in an immunocompromised patient: a case report.Journal of medical case reports · 2024Article
- The Impact of Urinary Catheterization on the Antibiotic Susceptibility of ESBL-Producing Enterobacterales: A Challenging Duo.Antibiotics (Basel, Switzerland) · 2024Article
- Current epidemiologic features and health dynamics of ESBL-producingBiosafety and health · 2024Review
- Influence of preoperative urine culture and bacterial species on urogenital sepsis after ureteral flexible lithotripsy in patients with upper urinary tract stones.Frontiers in medicine · 2024Article
- Susceptibility to Fosfomycin and Nitrofurantoin of ESBL-PositiveJournal of Korean medical science · 2023Article
- Antimicrobial Resistance Patterns and Risk Factors Associated with ESBL-Producing and MDRMicroorganisms · 2023Article
- High prevalence of β-lactam and fluoroquinolone resistance in various phylotypes of Escherichia coli isolates from urinary tract infections in Jiroft city, Iran.BMC microbiology · 2023Article
- ESBL-Producing and Non-ESBL-ProducingInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of the study was to investigate the antimicrobial susceptibility and extended-spectrum beta-lactamase (ESBL) positive rates of MATERIALS AND
methodsA total of 809
resultsThe antimicrobial agents with susceptibility rates of greater than 95% included imipenem (99.9%), colistin (99.6%), ertapenem (98.9%), amikacin (98.3%), cefmetazole (97.9%), nitrofurantoin (96%), and fosfomycin (95.4%). However, susceptibilities to cephalosporins (varying from 58.6% to 74.9%) and levofloxacin (48.8%) were relatively low. In the phenotypic detection of ESBLs, ESBL-positive isolates made up 38.07% of
conclusionOur study indicated high prevalence of ESBL in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.